Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs
- 1 January 2009
- journal article
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 11 (9), 1823-1827
- https://doi.org/10.1039/b904616j
Abstract
The first example of a trimorphic cocrystal involving two active pharmaceutical ingredients, ethenzamide and gentisic acid, is reported; metastable polymorphs convert to the stable form upon solid-state grinding; pharmaceutical cocrystals involving two or more APIs have potential relevance to combination drugs.Keywords
This publication has 44 references indexed in Scilit:
- Designing Co-Crystals of Pharmaceutically Relevant Compounds That Crystallize with Z′ > 1Crystal Growth & Design, 2008
- The Co‐Crystal Approach to Improve the Exposure of a Water‐Insoluble Compound: AMG 517 Sorbic Acid Co‐Crystal Characterization and PharmacokineticsJournal of Pharmaceutical Sciences, 2008
- Polymorphism in Carbamazepine CocrystalsCrystal Growth & Design, 2008
- Performance comparison of a co-crystal of carbamazepine with marketed productEuropean Journal of Pharmaceutics and Biopharmaceutics, 2007
- Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution ratesAdvanced Drug Delivery Reviews, 2007
- A “hidden” co-crystal of caffeine and adipic acidChemical Communications, 2007
- Combination-drug products: Benefit or burden to patients?American Journal of Health-System Pharmacy, 2006
- Lactose as a Low Molecular Weight Carrier of Solid Dispersions for Carbamazepine and Ethenzamide.CHEMICAL & PHARMACEUTICAL BULLETIN, 1999
- Modifying effects of a mixture of acetaminophen, aspirin, dipyrone and ethenzamide on a multiorgan initiation model and its carcinogenicity in male F344 ratsCancer Letters, 1998
- Crystallization of polymorphs: the effect of solventJournal of Physics D: Applied Physics, 1993